PPAR Gamma Activators and Glioma Cell Migration
Author Information
Author(s): Sebastian Seufert, Roland Coras, Christian Tränkle, Darius P. Zlotos, Ingmar Blümcke, Lars Tatenhorst, Michael T. Heneka, Eric Hahnen
Primary Institution: University of Cologne
Hypothesis
The inhibition of glioma cell motility and invasiveness by PPARγ activators is primarily driven by the inhibition of TGF-β signaling.
Conclusion
Troglitazone and its derivative effectively inhibit glioma progression and brain invasion.
Supporting Evidence
- Troglitazone and its derivative Δ2-troglitazone inhibit TGF-β1 release from glioma cells.
- Δ2-troglitazone effectively blocks glioma progression in an organotypic environment.
- PPARγ activation is not essential for the inhibition of glioma cell viability.
Takeaway
This study shows that certain drugs can stop brain cancer cells from moving and spreading, which could help treat gliomas.
Methodology
The study involved in vitro and ex vivo assays to test the effects of PPARγ activators on glioma cell migration and invasion.
Limitations
The exact mechanisms by which PPARγ activators exert their effects remain unclear.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website